DDInter1382 DDInter1676
Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first dose of a course of chemotherapy and is the only drug of its class approved for this use by the U.S. Food and Drug Administration. As of 2008, it is the most recent 5-HT3 antagonist to enter clinical use.
Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). It was approved by the FDA on March 26, 2019 and by Health Canada on February 20, 2020. This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA label]. Multiple Sclerosis (MS) is an autoimmune disease of the central nervous system that is chronic and inflammatory, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years of life. Symptoms may include but are not limited to fatigue, gait changes, bowel or bladder dysfunction, abnormal muscle twitching, vision disturbance, and depressing or mood swings. MS is one of the most common causes of neurological disability in young adults and is found to occur more frequently in women than in men.[A176474,L5792]
Palonosetron {u} (Compound) resembles {v} (Compound) Praziquantel
Palonosetron {u} (Compound) binds {v} (Gene) HTR3A
Palonosetron {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin 3 Receptor Antagonists
Palonosetron {u} (Compound) causes {v} (Side Effect) Malnutrition
Palonosetron {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Palonosetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ezogabine
Palonosetron {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluconazole
Palonosetron {u} may lead to a major life threatening interaction when taken with {v} Lefamulin
Palonosetron {u} may lead to a major life threatening interaction when taken with {v} Mirtazapine
Palonosetron (Compound) resembles Praziquantel (Compound)
Palonosetron (Compound) binds HTR3A (Gene)
Palonosetron (Compound) is included by Serotonin 3 Receptor Antagonists (Pharmacologic Class)
Palonosetron (Compound) causes Malnutrition (Side Effect)
Palonosetron may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Ezogabine
Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole
Palonosetron may lead to a major life threatening interaction when taken with Lefamulin
Palonosetron may lead to a major life threatening interaction when taken with Mirtazapine